Analyst Price Targets — ABBV
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 24, 2026 9:07 pm | Trung Huynh | RBC Capital | $260.00 | $228.44 | StreetInsider | RBC Capital Starts Abbvie (ABBV) at Outperform |
| February 19, 2026 9:17 pm | — | Barclays | $275.00 | $224.35 | TheFly | AbbVie initiated with an Overweight at Barclays |
| February 18, 2026 11:41 am | — | Piper Sandler | $299.00 | $232.86 | TheFly | AbbVie price target raised to $299 from $289 at Piper Sandler |
| February 5, 2026 12:24 pm | — | UBS | $230.00 | $217.42 | TheFly | AbbVie price target lowered to $230 from $240 at UBS |
| February 4, 2026 7:35 pm | Gavin Clark-Gartner | Evercore ISI | $228.00 | $217.02 | TheFly | AbbVie price target lowered to $228 from $232 at Evercore ISI |
| January 28, 2026 11:57 am | Asad Haider | Goldman Sachs | $223.00 | $219.77 | StreetInsider | Goldman Sachs Reiterates Neutral Rating on Abbvie (ABBV) Ahead of Earnings |
| January 20, 2026 9:29 am | — | Berenberg Bank | $275.00 | $214.35 | TheFly | AbbVie price target raised to $275 from $270 at Berenberg |
| January 15, 2026 1:25 pm | Evan David Seigerman | BMO Capital | $258.00 | $217.74 | StreetInsider | BMO Capital Reiterates Outperform Rating on Abbvie (ABBV) |
| January 7, 2026 10:30 am | — | UBS | $240.00 | $223.93 | TheFly | AbbVie assumed with a Neutral at UBS |
| December 12, 2025 1:09 pm | — | Morgan Stanley | $269.00 | $222.48 | TheFly | AbbVie price target raised to $269 from $261 at Morgan Stanley |
Latest News for ABBV
In the Phase 3 AFFIRM study in adults with moderately to severely active Crohn's disease, risankizumab (SKYRIZI®) achieved superiority for the co-primary and ranked secondary endpoints at week 12 for induction delivered by subcutaneous (SC) injection versus placebo1 These data support strong efficacy of risankizumab in Crohn's disease while providing potential for an induction choice for patients1 The safety profile…
Bahl and Gaynor Inc. cut its holdings in shares of AbbVie Inc. (NYSE: ABBV) by 23.5% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,154,256 shares of the company's stock after selling 968,314 shares during the period. AbbVie
High-yield stocks are outperforming, with a clear rotation from growth to value driving strong returns for dividend-focused investors. Safe, high-yielding companies are still trading at discounts. These 3 are in the process of rerating, providing an appealing position to initiate a position.
111 Capital lessened its position in AbbVie Inc. (NYSE: ABBV) by 77.4% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 4,411 shares of the company's stock after selling 15,143 shares during the period. 111 Capital's holdings in AbbVie were worth $1,021,000 at the
Argent Trust Co lowered its stake in AbbVie Inc. (NYSE: ABBV) by 1.5% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 205,045 shares of the company's stock after selling 3,119 shares during the period. AbbVie accounts for about 1.7% of Argent Trust
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.